Flavonoid and experimental senolytic · Fact sheet

Fisetin

Also known as senolytic flavonoid · dietary fisetin

Fisetin is not an FDA-approved senolytic or anti-aging drug. Animal studies and early human mechanistic research justify clinical trials, but there is no proof that fisetin extends human life, reverses frailty, or prevents age-related disease.

In clinical trialsMostly animal or lab research

What is Fisetin?

Fisetin is a flavonoid found in small amounts in foods such as strawberries and apples.

In geroscience it is studied as a senolytic—a compound intended to preferentially remove some senescent cells—but cell type, exposure, and model strongly affect that claim.

Benefits & claims

A prominent mouse study reported reduced senescence markers, improved health measures, and longer lifespan.

Human trials now examine vascular function, frailty, and treatment-related physical decline, but a trial design or biomarker shift is not a clinical benefit.

What the evidence supports

  • Preclinical work supports a senolytic hypothesis and identified cell-type-specific effects.
  • Early human research may clarify target engagement, but meaningful clinical outcomes remain unproven.
Research areas
  • Cellular senescence
  • Frailty
  • Vascular function
  • Physical function after cancer treatment

Dosage & frequency

No established human regimen

Fisetin senolytic schedules remain investigational. Trial-specific intermittent exposure is not an established longevity prescription.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • A food-associated flavonoid and a high-exposure trial product are different contexts.

Interactions & precautions

  • Experimental senolytic schedules do not establish compatibility with anticoagulants, cancer medicines, or other high-exposure supplements.

What is still unresolved

  • An effective human senolytic schedule and the long-term risk of repeated courses remain unresolved.

Side effects & risks

  • A food constituent is not automatically safe at concentrated research exposure.
  • Human adverse-event data are too limited to define uncommon, interaction, or long-term risks.
  • Supplement identity, purity, and formulation may not match clinical-trial material.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Mostly animal or lab research

The most influential healthspan and lifespan findings are from mice and cell systems. Human work is early, mechanistic, small, or still recruiting and does not establish better function, fewer diseases, or longer life.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 4 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

Sharper thinking with initial tiredness

A 28-year-old reported feeling mentally sharper and less depressed after a brief exposure, with tiredness on the first day that then passed.

Reported use in this account

Product
Fisetin capsules; formulation not otherwise verified
Amount
2 grams per day, also described as 20 mg/kg/day
Frequency
Daily
Route
Not specified clearly
Duration
Two days

The author acknowledged a possible placebo effect. Promised laboratory follow-up was not visible; this does not establish senescent-cell removal or depression treatment.

Read the original account
Negative account · personal report

Feeling overstimulated and unable to sleep

Another commenter reported feeling unusually activated and having insomnia on both nights of a short exposure, while also drinking coffee.

Reported use in this account

Product
Product described as fisetin
Amount
1.2 grams
Frequency
Daily
Route
Not specified clearly
Duration
Two days

Other exposures described: Coffee

Caffeine and other influences were not controlled. The proposed explanation in the thread was speculation.

Read the original account

Approval status

Fisetin is being studied in human trials but has no FDA-approved drug use for senescence, frailty, cardiovascular aging, cancer recovery, or longevity. Supplement products are not FDA approved for effectiveness.

Small human senolytic trials

Fisetin has a small Phase 2 frailty trial record and early human mechanistic research, but no FDA-approved senolytic, frailty, or longevity indication.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether fisetin reliably clears clinically relevant senescent cells in people
  • Whether biomarker effects improve function, disease risk, or survival
  • Which tissues and populations could benefit or be harmed
  • Long-term safety and interactions

Summary

Fisetin is one of the better-known experimental senolytics, but its reputation still rests mainly on preclinical work. Human longevity benefit has not been shown.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedPreclinical fisetin healthspan and lifespan study

    Cell, tissue, and mouse evidence that motivated human senolytic research.

  2. clinical trialsClinicalTrials.gov: AFFIRM-LITE

    Small Phase 2 frailty trial record with no public outcomes result.

  3. pubmedEarly human fisetin vascular-aging study

    Mechanistic human study that does not establish longevity or disease prevention.

  4. fdaFDA: dietary supplements are not preapproved for effectiveness

    FDA explanation of the regulatory distinction between approved drugs and marketed dietary supplements.

How we assess sources · Suggest a correction